Novartis Stock: Stellar Q1 Results Exceed Expectations

Novartis delivered an impressive start to 2025, with first-quarter figures substantially surpassing market forecasts. The Swiss pharmaceutical giant reported revenue of $13.2 billion, representing a 12% increase compared to the same period last year (15% at constant exchange rates). This growth was primarily driven by higher sales volumes across key product lines. The company's financial strength was further highlighted by a remarkable 34% surge in net profit to $3.61 billion, with earnings per share climbing 40% to $1.83. These results demonstrate Novartis's operational excellence and have triggered a positive response from investors, with the stock breaking through an important psychological barrier following the announcement.

Upgraded Outlook for 2025

Following the strong quarterly performance, Novartis management has raised its full-year guidance for the ninth consecutive time—a clear testament to the company's consistent delivery and market confidence. The pharmaceutical firm now anticipates revenue growth at the higher end of the previously forecasted "mid to high single-digit" range. More significantly, expectations for the adjusted operating income have been revised upward to "low double-digit" growth, compared to the earlier projection of "high single-digit to low double-digit" increases. This enhanced outlook reflects management's growing optimism about Novartis's market position and potential for continued strong performance throughout 2025.

Ad

Fresh Novartis information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Source StockWorld